MedTrace Logo

Single Dose ADME Study of [14C]SJP-0008 in Healthy Male Subjects

NCT05320861 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-04-11

No results posted yet for this study

Summary

This single centre, open-label, non-randomised, single period, single-dose study in healthy male subjects was designed and conducted to assess the mass balance recovery, PK, metabolite profile and metabolite identification of SJP-0008.

Conditions

  • Healthy Volunteers

Interventions

DRUG

[14C]SJP-0008

Single oral dose of \[14C\]SJP-0008

Sponsors & Collaborators

  • Quotient Sciences

    collaborator INDUSTRY

  • Senju Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Somasekhara Menakuru · Quotient Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-24
Primary Completion
2021-11-02
Completion
2021-11-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05320861 on ClinicalTrials.gov